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The enterovirus 71 (EV71) outbreak in Taiwan in 1998 proved fatal in many chil-
dren. A seroepidemiological study performed prior to the 1998 outbreak showed 
pre-epidemic (1997) EV71 seroprevalence rates to be about 60−70% in adults and 
children older than 6 years of age. A retrospective case review carried out from 
1980−81 identified 16 cases of hand, foot and mouth disease associated with central 
nervous system involvement, two of whom died soon after hospitalization. There were 
405 severe cases and 78 deaths reported in the 1998 epidemic, and dozens of fatal 
EV71 cases were still reported from 2000 to 2002. A stage-based management strat-
egy was developed to reduce fatality, but most survivors of brainstem encephalitis 
with cardio pulmonary failure have neurologic sequelae and impaired cognition. 
Continuous clinical and laboratory surveillance of EV71 disease is required to enable 
earlier implementation of control and prevention measures. Development of EV71-
specific antiviral therapy, a novel class of imidazolidinones, and development of a 
vaccine are ongoing.
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1. Introduction
Enteroviruses belong to the Picornaviridae, a fam-
ily of single-stranded positive-sense RNA viruses. 
Se rologic studies using neutralization tests with 
antisera against enteroviruses have identified more 
than 67 human enterovirus serotypes: poliovirus 
serotypes 1−3, 23 Coxsackie A virus serotypes, 6 
Coxsackie B virus serotypes, 31 echovirus sero-
types, and the numbered enterovirus serotypes 
(enteroviruses 68−71). Clinically, polioviruses and 
enterovirus 71 (EV71) are among the most important 
and severe enteroviruses and are responsible for 
many deaths and severe sequelae. Since the erad-
ication of poliovirus by vaccination in Taiwan in 
2000, EV71 has been considered one of the most im-
portant enteroviruses. Continuous surveillance of 
its occurrence, investigation into its virulence and 
transmission, and the development of treatment 
strategies, including antiviral therapies and vaccines, 
are all required in order to improve the future con-
trol and outcomes of EV71 infection.
2.  EV71 in Taiwan Before the 1998 
Epidemic
EV71 was first isolated in California, USA, in 1969.1 
Since then, four epidemic outbreaks with high 
mortality have occurred: in Bulgaria in 1975 (44 
deaths),2 in Hungary in 1978 (47 deaths),3 in Malaysia 
in 1997 (at least 31 deaths),4 and in Taiwan in 1998 
(78 deaths).5
The EV71 outbreak in Taiwan in 1998 was well 
publicized, but EV71 existed in Taiwan before 1998. 
Our seroepidemiological study conducted prior to 
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the 1998 outbreak showed pre-epidemic (1997) EV71 
seroprevalence rates to be about 60−70% in adults 
and children older than 6 years of age.6 Lu et al 
examined serial serum antibody titers to EV71 in 
81 children born in 1988 who had yearly blood sam-
ples available for 1989 to 1994, and for 1997 and 
1999.7 They discovered that there was a yearly in-
cidence of EV71 seroconversion of 3−11% between 
1989 and 1997, and that 68% of those children had 
serological evidence of EV71 infection by 1997.7
EV71 was also isolated from patients in Taiwan 
with hand, foot, and mouth disease (HFMD) and 
poliomyelitis-like paralysis, as early as 1980 and 
1986.5,8 We performed a retrospective case review 
of all discharge notes from the Department of 
Pediatrics, National Taiwan University Hospital from 
1980 and 1981, and identified 16 cases of HFMD as-
sociated with central nervous system (CNS) involve-
ment: nine had polio-like syndrome, four had 
encephalitis or encephalomyelitis, one had cereb-
ellitis, and two had aseptic meningitis.9 Two patients 
with HFMD plus encephalitis died within 1 day of 
hospitalization, and one of them also had acute 
cardiopulmonary failure mimicking myocarditis,9 a 
clinical picture similar to that seen in the 1998 
EV71 epidemic. Twenty years later, at least one male 
patient was still suffering from the sequelae of 
polio-like syndrome and was therefore exempted 
from military service. The clinical severity of these 
cases in 1980−1981 was comparable to those seen 
in the 1998 EV71 epidemic.
These findings indicate that EV71 had been cir-
culating in Taiwan for at least 17 years before 1998, 
though its clinical significance had not been inves-
tigated. It is likely that severe cases of EV71 had 
occurred previously, but were not recognized. The 
pre-epidemic EV71 seroprevalence rates were in-
versely correlated with mortality and morbidity.6 
Among the cohort of 81 children, Lu et al found 
that the annual EV71 seroconversion rates (3−4%) 
between 1994 and 1997 were significantly lower 
than the rates (7−11%) before 1994.7 It is likely that 
there was a lower incidence of EV71 infection be-
tween 1994 and 1997, and that the accumulation 
of susceptible hosts that exceeded the threshold 
density might have triggered the 1998 outbreak. 
However, changes in EV71 neurovirulence and host 
genetic factors are also thought to have affected 
clinical outcomes.
3.  Surveillance Systems for Severe 
Enterovirus Cases in Taiwan
A physician-based sentinel surveillance system for 
infectious diseases was established in Taiwan in 
1989 and has been operated by the Ministry of 
Health since then.10 This system originally involved 
850 physicians, 8.7% of the primary care physicians 
in Taiwan. HFMD and herpangina were included in 
the system, following an outbreak of EV71-related 
HFMD in Malaysia in 1997. Because of a rapid in-
crease in the numbers of severe and fatal cases of 
HFMD, a hospital-based reporting system for moni-
toring such cases was initiated in May 1998. From 
June 1998, both physician-based and hospital-based 
surveillance systems have been maintained simul-
taneously.10 The total number of HFMD/herpangina 
cases reported by the physician-based sentinel 
surveillance system was 129,106; the number of 
severe cases peaked in early June, around the same 
time as the peak in HFMD cases.5 There were 405 
severe cases and 78 deaths during the 1998 epi-
demic.5 From 1998 to 2005, a seasonal variation in 
the number of severe enterovirus cases was ob-
served, with the annual peak occurring in the second 
quarter. Deaths due to severe enterovirus infec-
tions varied from year to year, with most (92%) cases 
occurring in children younger than 4 years of age.11 
Children infected with EV71 had higher risks of pul-
monary edema/hemorrhage and encephalitis than 
those infected with other enteroviruses.11
The Taiwan Centers for Disease Control (CDC) 
also established virological surveillance systems for 
enterovirus and influenza, with 10 viral contract lab-
oratories for surveillance located in different areas 
of Taiwan in 2000, and 13 in 2007.12 Table 1 shows 
the numbers of severe and fatal enterovirus cases 
in Taiwan from 1998 to 2006, and the number of 
EV71 cases among the fatal cases. Table 2 shows the 
five most common enterovirus serotypes in Taiwan 
from 1998 to 2006.13 EV71 was the most common cir-
culating serotype in 1998, 2000 and 2001 (Table 2),13 
and more severe and fatal enteroviral cases oc-
curred in these years than in the other years. We 
therefore predict that more severe and fatal en-
terovirus cases will occur when the major circulating 
serotype is EV71. The surveillance systems, both 
clinical and laboratory-based, will continue to serve 
public health workers and enable the earlier imple-
mentation of control and prevention measures to 
contain or limit the spread of EV71, reducing the 
numbers of severe and fatal enterovirus cases.
4.  Routes and Rates of EV71 
Transmission
Humans are the only known natural hosts of entero-
viruses. Enteroviruses can infect humans through 
gastrointestinal cells, and through the respiratory 
tract. Enteroviruses are usually transmitted through 
fecal-oral contact, and sometimes through droplet/
aerosol transmission. Furthermore, enteroviruses can 
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live for over 24 hours in stainless steel containers, 
and such contaminated objects may be a means of 
viral transmission. These viruses can live in low pH 
conditions (pH 3), and are resistant to 70% ethanol 
and ether. They can remain active at room temper-
ature for several days.
We found that the isolation rate of EV71 from 
throat swabs (93%) was significantly higher than that 
from rectal swabs or feces (30%) in EV71-infected 
cases with acute illnesses,14 suggesting that the oral-
oral route or droplet transmission might be more 
important routes of transmission than the fecal-oral 
route during acute EV71 illness.
How high is the rate of enterovirus transmission? 
The secondary household transmission rates of en-
teroviruses vary, as shown for poliovirus, enterovirus 
70 and Coxsackievirus A24.15−17 EV71 seropositivity 
was found to be concordant among siblings in our 
previous seroepidemiological study, suggesting that 
household transmission plays an important role in 
the spread of EV71.6 We therefore performed a 
prospective family cohort study of EV71 household 
transmission. We studied 433 family members from 
94 families in which EV71 had been isolated from at 
least one family member. The overall EV71 trans-
mission rate between household contacts was 52% 
(176/339): 84% (70/83) siblings, 83% (19/23) cousins, 
41% (72/175) parents, 28% (10/36) grandparents and 
26% (5/19) uncles/aunts.18 EV71 household transmis-
sion rates were high for children, medium for par-
ents and low for other adults. Being male and less 
than 6 years old were factors associated with in-
creased risks of EV71 infection.18 The EV71 isolation 
rate from child household contacts was 39% (41/106), 
which was significantly higher than the 4.3% (10/233) 
EV71 isolation rate from adult household contacts 
(p < 0.001).18 The isolation rates from adult household 
contacts were possibly lower due to the presence of 
protective antibodies from previous exposures, or 
due to lower concentration of the virus in secre-
tions. These figures suggest that infected children 
are more able to transmit the virus than are infected 
adults.
Why is the household transmission rate for chil-
dren so high? Long periods of viral shedding may 
account for widespread transmission of enteroviral 
diseases, as is the case for polio and Coxsackievirus 
infections.15 In a previous study, we found that EV71 
was present in the stools of infected patients for 
up to 5 weeks.19 Close household contact, higher 
viral load, and long viral shedding periods may there-
fore account for the high household transmission 
rate among children.
Most secondary cases in the family develop 
disease 3−4 days after the index cases. Case-to-
case intervals are shown in Figure 1. The incuba-
tion period is usually 3−4 days, but can be as long 
as 10 days or more. Some household members may 
develop the disease on the same day, or 1 day 
Table 1 Number of cases of severe and fatal enterovirus infections in Taiwan from 1998 to 2006
Year
 Number of  Number of fatal cases EV71 number (%) among 
 severe cases  (severe case-fatality rate)  the fatal cases
1998 405 78 (19%) 34 (44%)
1999 35 9 (26%) 1 (11%)
2000 291 41 (14%) 25 (61%)
2001 393 58 (15%) 27 (47%)
2002 162 30 (19%) 8 (27%)
2003 70 8 (11%) 4 (50%)
2004 50 5 (10%) 5 (100%)
2005 142 16 (11%) 7 (44%)
2006 11 0 0
Total 1559 245 (15.7%)  111 (45.3%)
Data from CDC, Taiwan.
Table 2  Five most common enterovirus serotypes in 
Taiwan from 1998 to 2006
Year
 Rank
 1st 2nd 3rd 4th 5th
1998 EV71 CA2 CA16 CA4 CA6
1999 CB1 Echo4/30 CB3 CA16 CA10
2000 EV71 CA16 Echo9 CB3 CB4
2001 EV71 CA16 Echo4/30 Echo6 CB4
2002 CA16 Echo6 CB5 EV71 CA24
2003 CA16 EV71 Echo9 Echo11 CA6
2004 CA4 CB4 CA10 EV71 CB3
2005 CB3 CA16 EV71 CA6 CA5
2006 CA4 CA2 Echo18 CA5 CB2
Data from CDC, Taiwan, and modified from Reference 13. 
CB = Coxsackievirus B; CA = Coxsackievirus A; Echo = echovi-
rus; Echo4/30 = indistinguishable between echovirus 4 and 
echovirus 30.
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later, because they contracted their infections 
from the same asymptomatic person, possibly at 
home.
5.  Clinical Spectra and Stages of EV71 
Infection
The EV71 household study showed that only 6% of 
infected children, compared with 53% of infected 
adults, were asymptomatic.18 Interestingly, in the 
seroepidemiologic study, only 29% of the preschool 
children infected with EV71 developed HFMD/
herpangina,6 suggesting that about 70% of children 
with community-acquired infections might be 
asymptomatic.
According to our clinical studies,20−22 symptomatic 
EV71 infection can progress through four stages: 
HFMD/herpangina (Stage 1), CNS involvement (Stage 
2), cardiopulmonary failure (Stage 3), and convales-
cence (Stage 4). Most EV71 cases in these studies re-
mained at Stage 1, though some progressed to Stage 
2, and a few advanced to the most severe condition—
Stage 3.
5.1.  Stage 1: Uncomplicated EV71 illness
Uncomplicated EV71 illnesses include HFMD (about 
80%), herpangina (about 10%), pharyngitis, nonspe-
cific febrile illness (about 10%), generalized viral 
exanthema, and enteritis. The patients may have 
suffered from fever for 1−3 days, with temperatures 
sometimes reaching > 39ºC. HFMD patients develop 
oral ulcers on the tongue and buccal mucosa, and 
a vesicular rash or small erythematous maculopa-
pular rash on their hands, feet, knees, and/or but-
tocks. The EV71-induced vesicular or maculopapular 
rash over the extremities is sometimes so incon-
spicuous that it can be overlooked by parents and 
even by doctors. Herpangina includes oral ulcera-
tion on anterior tonsillar pillars, the soft palate, 
buccal mucosa and/or the uvula. Oral ulceration 
causes pain while eating or drinking, and patients 
may need intravenous fluid supplementation if de-
hydration occurs. About 10% of the EV71 cases have 
febrile illness or pharyngitis without the usual 
HFMD/herpangina.
5.2.  Stage 2: Complicated EV71 illness with 
CNS involvement
EV71 patients may develop complications 1−5 days 
after the onset of the illness. After the initial HFMD, 
herpangina or febrile illness and an intermittent 
fever that usually lasts 3−7 days, some patients 
may experience CNS involvement including menin-
gitis, encephalitis, polio-like syndrome, or enceph-
alomyelitis with or without pulmonary edema. Even 
when the clinical manifestations, cerebrospinal fluid 
(CSF) pleocytosis and image studies all suggest CNS 
involvement, EV71 is seldom isolated from the CSF. 
Huang et al23 described three EV71-related neuro-
logic syndromes in the Taiwan outbreak: aseptic 
meningitis, acute flaccid paralysis, and rhomben-
cephalitis (brain stem encephalitis). EV71 cases 
with aseptic meningitis usually suffer from myo-
clonic jerks during sleep, vomiting, headache and/
or irritable crying. They have mild, if any, neck 
stiffness and they usually recover within 3−7 days 
after hospitalization. The most common initial symp-
toms of EV71 encephalitis are myoclonic jerks dur-
ing sleep, and these are followed by other symptoms 
or signs of encephalitis. Patients may also show other 
signs of changes in consciousness such as lethargy, 
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Figure 1 The interval in days between first case and secondary case in the same household. There were 18 households 
with at least two cases who became ill on the same day, none of which had an identified extra-household source of 
EV71 infection. This indicated that they might have had contact with the same asymptomatic EV71-infected person 
within or outside the household.
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sleepiness or coma, seizure attacks, ataxia, and 
cranial nerve palsies, such as abducens palsy, fa-
cial palsy, dysphagia, upward gaze and nystagmus. 
Subtle symptoms of increased sympathetic tone, 
such as insomnia, profuse sweating, paralytic ileus, 
neurogenic bladder, panic or increased startle re-
flex have also been recorded. If cases of encepha-
litis do not advance to Stage 3, they usually recover 
without sequelae 5−10 days later. EV71 cases with 
poliomyelitis-like syndrome have asymmetric acute 
limb weakness and decreased reflexes, with no dis-
turbance of limb sensation. Children suddenly be-
come unable to walk or raise their arms, or they 
easily fall 3−7 days after developing HFMD or her-
pangina. About half of the EV71 polio-like cases 
experience long-term sequelae, including limb 
weakness and atrophy. Patients with encephalomy-
elitis exhibit symptoms of both encephalitis and 
poliomyelitis-like syndrome.
Of the imaging methods used to investigate CNS 
involvement, brain or spinal computed tomography 
(CT) usually produce negative findings in cases of 
EV71 CNS infection, and CT is therefore not the im-
aging method of choice. Magnetic resonance imag-
ing (MRI) is more suitable, and MRI studies usually 
show hyperintensity in the CNS lesions on T2-
weighted images. The major CNS lesions in brain-
stem encephalitis and cerebellitis occur in the 
medulla oblongata, pons, midbrain, and the dentate 
nuclei of the cerebellum. In polio-like syndrome, 
lesions have been found in the anterior horn of the 
spinal cord (Figure 2). Some patients may present 
with normal MRI results, while patients with enceph-
alomyelitis may have lesions of both the brainstem 
and the spinal cord (Figure 3). In follow-up MRI ex-
aminations of patients with sequelae, lesions have 
been shown to persist for 1−3 years after initial 
acute illness.
5.3.  Stage 3: Cardiopulmonary failure or 
pulmonary edema
Several hours to 2 days after the onset of CNS in-
volvement, some patients may advance to Stage 
3A, when they develop sudden signs of tachycardia 
(135−250 beats per minute), tachypnea, and cya-
nosis. Patients are usually alert, except for mild 
lethargy, and have sometimes been found to have 
transient hypertension, lasting for several hours to 
2 days. Laboratory findings include hyperglycemia 
and leukocytosis. Chest X-ray films show alveolar 
Figure 2 MRI of an EV71 polio-like case. Hyperintense 
lesions (arrows) are seen in the anterior horn of the spinal 
cord on T2-weighted image.
A
B
Figure 3 MRI of a case of EV71 encephalomyelitis plus 
pulmonary edema. (A) Sagittal view of T2-weighted image 
show hyperintense lesions in the posterior portion of 
the pons and the medulla and also in the anterior por-
tion of the C-spinal cord. (B) Coronal view show hyperin-
tense lesions in the posterior portion of the pons-medulla 
junction.
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density and no cardiomegaly, and in most cases ex-
amined during the 1998 epidemic, became completely 
white within the lungs within 12 hours. Electrocar-
diographic examination shows sinus tachycardia and 
no arrhythmia. Ejection fractions on cardiac echo-
graphy range from about 40%−80%. Once intubated, 
children may produce a white frothy secretion, fol-
lowed by a pink frothy fluid, and sometimes fresh 
blood, from the endotracheal tube. Patients fre-
quently suffer from persistent fever and profuse 
sweating during critical points of this stage.
Progressive hypotension or shock, oliguria or 
anuria, tachycardia and decreased levels of con-
sciousness have been found if the disease progresses 
to Stage 3B.22 Nearly 80% of children who reached 
this stage died within 12 hours of intubation, during 
the 1998 epidemic, but the fatality rate decreased 
to 30%−40% in 2000−2002, after the introduction 
of stage-based management.21 This significantly 
lower mortality may have been due to earlier and 
better intensive care, while earlier intubation, ear-
lier usage of inotropic agents, and intensive care 
also reduced the rate and severity of pulmonary 
edema/hemorrhage after the year 2000.
Pathological studies of cases with pulmonary 
edema have revealed extensive inflammation in the 
CNS, with predominant lesions in the brain stem 
and spinal cord.24 Marked pulmonary edema with 
focal hemorrhage, with no evidence of myocarditis, 
has also been reported. EV71 has been isolated from 
CNS tissues but not from other tissues. Autopsy 
findings in Taiwan have been similar to those re-
ported in Malaysia.25 EV71 was usually isolated from 
the brain, medulla, and cervical, thoracic and lum-
bar spinal cord, as well as from throat and rectal 
swabs, and sometimes from the blood. MRI studies 
of cases with cardiopulmonary failure have usually 
shown hyperintensity of the posterior aspect of the 
medulla (Figure 3B), with or without involvement 
of the cervical spinal cord on T2-weighted images.
Immunopathogenesis studies found that EV71 
cases with both encephalitis and cardiopulmonary 
failure had much higher white blood cell counts, 
and higher levels of blood glucose, systemic pro-
inflammatory cytokines such as interleukin (IL)-6, 
tumor necrosis factor-α, interleukin-1β, γ-interferon, 
IL-10, and IL-13 than those patients with EV71 en-
cephalitis alone.26−28 Levels of CSF IL-6 in EV71 
study patients were consistently higher during the 
initial 2 days of CNS involvement, regardless of the 
presence of pulmonary edema.28 Patients with pul-
monary edema had lower circulating CD4+ T-cells, 
CD8+ T-cells, and natural killer cells.27 The CD40-
ligand expression on T-cells was significantly re-
duced in children with meningoencephalitis.29 
However, EV71-neutralizing antibody titers were 
detectable in children with pulmonary edema, with 
meningoencephalitis alone, and with uncomplicated 
illness, but there were no differences in EV71 neu-
tralizing titers.29,30 We also measured the lympho-
cyte proliferation response and EV71-stimulated 
cellular response of Th1/Th2 cytokines and chemo-
kines, and found that EV71 cases involving brain-
stem encephalitis plus cardiopulmonary failure had 
significantly lower phytohemagglutinin stimulation 
indices and significantly lower cellular γ-interferon 
(p = 0.04), IL-1β (p = 0.04), IL-6 (p = 0.04), and tumor 
necrosis factor-α responses (p = 0.04), and lower cel-
lular macrophage inflammatory protein-1α (p = 0.04) 
responses, compared with other cases (p = 0.04).30 
These results suggest that a lower EV71-specific 
cellular response, rather than humoral immunity, 
may be associated with the immunopathogenesis 
of EV71-related cardiopulmonary failure.
5.4.  Stage 4: Convalescence and long-term 
sequelae
We have assessed the neurological development 
and cognitive function of children in Taiwan who 
survived EV71 infection with CNS involvement be-
tween 1998 and 2003.31 The prospective study in-
cluded 142 children with clinically confirmed EV71 
infection who experienced mild CNS involvement 
including meningitis (n = 61), severe CNS involve-
ment including encephalitis, encephalomyelitis or 
polio-like syndrome (n = 53), or cardiopulmonary 
failure following CNS infection (n = 28). Nine of the 
16 polio-like cases (56%) and one of the five en-
cephalomyelitis cases (20%) experienced sequelae 
involving limb weakness/atrophy. Eighteen of the 
28 cases with cardiopulmonary failure (64%) after 
CNS involvement experienced limb weakness and 
atrophy, 17 (61%) required tube feeding, and 16 (57%) 
required ventilator support. Delayed neurodevelop-
ment was found in only one case (5%) with severe 
EV71 CNS involvement and in 21 cases (75%) with 
cardiopulmonary failure following CNS infection 
(p < 0.001). The age of the children at the time of 
disease onset in the most clinically severe group 
was significantly lower than that in the other groups 
(p < 0.001). The effects of EV71 infection on neuro-
logical development and cognitive function appear 
to be strongly related to the severity of CNS involve-
ment and the patient’s age at disease onset.31
6.  Treatment Strategy: Stage-based 
Management
Nearly 90% of patients with cardiopulmonary fail-
ure in Taiwan’s 1998 epidemic died.20 In 2000, with 
the approval of Taiwan’s Enterovirus Ad Hoc Com-
mittee and the Taiwan CDC, we developed a disease 
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management program that varied according to the 
different stages of EV71 infection, with the aim of 
improving survival rates (Table 3).21
The clinical stages have been described above. 
Patients with Stage 1 disease (uncomplicated ill-
ness) require symptomatic treatment only. Patients 
identified as having Stage 2 disease (complicated 
illness with CNS involvement) are hospitalized, and 
are treated with fluid restriction and the adminis-
tration of osmotic diuretics for those with signs 
of increased intracranial pressure, and furosemide 
for those suspected of having fluid overload. Intra-
venous immunoglobulin, usually 1 g/kg, is adminis-
tered, and heart rate, blood pressure, oximeter, 
coma scale and blood sugar are closely monitored. 
Patients are managed in the intensive care unit if 
they have tachycardia, tachypnea/apnea, hyper-
tension/hypotension, signs of increased intracranial 
pressure, or hyperglycemia.
Patients identified as having Stage 3 disease 
(cardiopulmonary failure or pulmonary edema) are 
put on ventilator support and administered inotropic 
agents. These patients can be subdivided into Stage 
3A, having tachycardia, hypertension and/or pul-
monary edema, and Stage 3B, having hypotension.22 
Treatment of Stage 3A includes intensive care man-
agement with continuous fluid restriction, adminis-
tration of milrinone (0.25−0.75 μg/kg/min) to control 
severe hypertension and to increase cardiac output, 
early intubation with positive pressure mechanical 
ventilation, with increased positive end expiratory 
pressure for pulmonary edema. High-frequency 
oscillatory ventilation is considered if pulmonary 
edema or hemorrhage persists, or when severe hyp-
oxemia develops. When a patient’s blood pressure 
drops below the normal range for his or her age, the 
disease is considered to have moved into stage 3B. 
In some cases, blood pressure is very unstable, re-
quiring fine adjustments of inotropic agents such as 
dopamine (5−15 μg/kg/min) and epinephrine (0.05− 
0.4 μg/kg/min). Extracorporeal membrane oxygen-
ation may be used if these strategies fail to maintain 
satisfactory blood pressure or tissue perfusion.
For Stage 4 (convalescence) patients, rehabilita-
tion is provided for limb weakness/atrophy, dys-
phagia, diaphragm dysfunction, apnea or central 
hypoventilation. Sufficient chest care is necessary 
to avoid recurrent pneumonia, and some cases may 
need long-term tracheostomies, and may need to 
be transferred to respiratory care centers.
This stage-based management strategy has been 
associated with a reduction in the fatality rate of 
EV71-related cardiopulmonary failure, compared 
with the situation in 1998, but 75% of the survivors 
of EV71-related cardiopulmonary failure still suffer 
from severe sequelae.31 These data are based on 
historical comparisons rather than on prospective 
case-controlled studies, and we therefore need to 
be cautious in interpreting the results concerning 
stage-based management. It seems clear however 
that better preventive and treatment strategies 
for EV71 are still sorely needed.
7.  Antiviral Agents
Since EV71 can cause severe diseases resulting in se-
rious sequelae or death, EV71-specific antiviral ther-
apy may help to improve the clinical outcome. The 
replication cycle of enteroviruses involves several 
Table 3 Clinical staging and management of enterovirus 71 infection
Stage Clinical manifestations Management
1 HFMD/herpangina Symptomatic treatment only
2 CNS involvement Fluid restriction, osmotic diuretics for increased intracranial pressure, and 
  furosemide for fluid overload (CVP > 8 cmH2O), intravenous immunoglobulin for
  encephalitis and/or polio-like syndrome and close monitoring of heart rate, 
  blood pressure, oxygenation, coma scale and blood glucose
3 Cardiopulmonary failure
3A Hypertension/ Phosphodiesterase inhibitor, milrinone, to increase cardiac output, early 
 pulmonary edema  intubation with positive pressure mechanical ventilation with increased positive
  end expiratory pressure for pulmonary edema, and high frequency oscillatory
  ventilation if pulmonary edema/hemorrhage persists or severe hypoxemia
  develops
3B Hypotension Add inotropic agents such as dopamine and epinephrine 
4 Convalescence Rehabilitation for limb weakness, dysphagia, apnea or central hypoventilation, 
  and sufficient chest care to avoid recurrent pneumonia
HFMD = hand, foot, and mouth disease; CNS = central nervous system; CVP = central venous pressure.
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steps, including viral attachment, uncoating, viral 
RNA replication, and viral protein synthesis and 
processing, all of which provide potential targets 
for the development of antiviral drugs. Capsid-
binding agents, which prevent viral attachment and 
receptor-mediated uncoating, are among the most 
promising antiviral agents.32
The VP1 hydrophobic pocket generally contains 
unidentified natural molecules (pocket factor), 
which may stabilize the integrity of the virus and 
modulate the uncoating of its receptors. Pleconaril 
is a novel agent for the treatment of picornaviral 
infections, including enteroviruses and rhinoviruses. 
Absorption of the drug through the gastrointestinal 
tract is good, and concentrations in serum and CSF 
exceeding 0.1 mg/mL are easily attained following 
oral administration of a standard dose of the liquid 
formulation. Pleconaril demonstrates excellent in 
vitro antiviral activity against most enteroviruses. 
Furthermore, Groarke and Pevear reported antiviral 
activity of oral pleconaril in three animal models 
of lethal enterovirus infection: Coxsackievirus se-
rotype A9 infection in suckling mice, Coxsackievirus 
serotype A21 strain Kenny infection in weanling 
mice, and Coxsackievirus serotype B3 strain M in-
fection in adult mice.33 Treatment with pleconaril 
increased the survival rate in all three models using 
both prophylactic and therapeutic dosing regimens.33 
This drug is currently undergoing late-stage clinical 
trials for the treatment of viral meningitis and 
viral respiratory infections.
However, pleconaril has failed to neutralize the 
cytopathic effects of EV71 isolates from the Taiwan 
1998 outbreak on cultured cells.34 By using the 
skeleton of pleconaril and its related molecules, 
so-called WIN compounds, as a template, rational 
design, synthesis, and structure-activity relationship 
studies have led to the development of a novel class 
of imidazolidinones with significant antiviral activi-
ty.34 These synthetic compounds were evaluated for 
anti-EV71 activity, and some analogs were found that 
inhibited all EV71 genotypes, and possessed antiviral 
activity against Coxsackieviruses A9, A24, B1, B3, and 
B5, echovirus 9 and enterovirus 68.34
Pyridyl imidazolidinones were identified using 
computer-assisted drug design. A virological inves-
tigation has demonstrated that BPR0Z-194, one of 
the pyridyl imidazolidinones, targets the EV71 capsid 
protein VP1. Time-course experiments revealed that 
BPR0Z-194 effectively inhibited virus replication in 
the early stages, implying that this compound might 
be able to inhibit viral adsorption and/or viral RNA 
uncoating.35
In addition to pyridyl imidazolidinones, a series 
of pyrazolo[3,4-d]pyrimidines were synthesized 
and their antiviral activities were evaluated in 
plaque reduction assays. There has been remarkable 
evidence showing this class of compounds to be very 
specific for human enteroviruses, including EV71. 
Some derivatives have proved to be highly effective 
in inhibiting enterovirus replication at nanomolar 
concentrations. Structure-activity relationship stud-
ies revealed that the phenyl group at the N-1 posi-
tion and the hydrophobic diarylmethyl group at 
the piperazine largely influenced the in vitro anti-
enteroviral activity of this new class of potent an-
tiviral agent. It was found that the pyrazolo[3,4-d]
pyrimidines with a thiophene substituent (e.g., com-
pounds 20−24) generally exhibited high activity 
against Coxsackievirus B3 (50% inhibition concen-
tration, IC50 = 0.06−0.089 μM) and moderate activity 
against EV71 (IC50 = 0.32−0.65 μM), with no apparent 
cytotoxic effect on rhabdomyosarcoma cell lines 
(50% cytotoxic concentration, CC50 > 25 μM).36 These 
promising anti-EV71 drugs are being tested in ani-
mal studies in Taiwan and may enter clinical trials 
if the animal studies show positive results.
8.  Prevention and Vaccine Development
Hand washing precautions have been in practice 
since the 1998 epidemic in Taiwan. Hand washing is 
the standard preventive measure targeting the fecal-
oral transmission route, but has limited efficacy in 
preventing droplet transmission. Furthermore, youn-
ger infected children have higher virus isolation rates 
as well as higher transmission abilities, and these 
young children are not usually able to consistently 
follow adequate hand washing routines.
Previous research has demonstrated a higher 
rate of EV71 isolation from throat swabs than from 
rectal swabs or stools (90% vs. 32%, respectively),14 
and very high household transmission among chil-
dren.18 We speculate that respiratory transmission 
by droplets from the oral cavity may explain the 
high secondary infection rate within households 
and in kindergartens in Taiwan despite hand wash-
ing precautions. Isolation of infected patients within 
single rooms and masks for the patients and their 
close contacts may therefore be recommended for 
the prevention of respiratory droplet transmission 
of EV71. In Taiwan, home isolation of kindergarten 
or elementary school students was suggested for 1 or 
2 weeks to prevent droplet transmission within kin-
dergartens or schools. It was suggested that younger 
children (< 3 years old) should refrain from attending 
kindergartens during the EV71 epidemic, in order 
to reduce the risk of exposure to EV71.
Enterovirus excretion through stools can persist 
for up to 11 weeks and hand washing and general 
hygiene precautions should therefore be advocated 
during convalescence. We found that subclinical 
enterovirus (including EV71) infection could occur, 
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and that live vaccine poliovirus did not interfere 
with the invasion of other non-polio enteroviruses.19
Although the above preventive measures have 
been in practice for 10 years in Taiwan, dozens of 
fatal EV71 cases still occurred from 2000 to 2002. 
Furthermore, another EV71 outbreak occurred re-
cently in Taiwan, with about 340 severe enterovirus 
cases involving the CNS, and 10 fatalities from 
January to August 12, 2008.37 Development of a vac-
cine might prove to be the only effective measure 
against EV71. Since poliovirus was eradicated by 
polio vaccination, EV71 has become the most impor-
tant enterovirus affecting children, and is the top 
candidate for future vaccine development.
No EV71 receptor has yet been found, and no 
transgenic mouse model is available, but a newborn 
mouse model has been used.38 In that model, experi-
mental infection with EV71 induced death in neo-
natal mice in an age- and dose-dependent manner. 
The mortality was 100% following intraperitoneal 
inoculation of 1-day-old ICR mice, and this gradu-
ally decreased with increasing age at the time of 
inoculation (60% in 3-day-old mice and no deaths in 
mice older than 6 days of age). Two studies in Taiwan 
have demonstrated that an inactivated EV71 virus 
vaccine can protect against lethal EV71 infection in 
new born mice by passive immunization from immu-
nized mother mice or adult mice.38,39
Yu et al found that protection against EV71 
challenge in neonatal mice was seen following pas-
sive transfer of serum from actively immunized 
adult mice, 1 day after inoculation with the virus.38 
Pups from hyperimmune dams were resistant to 
EV71 challenge. Additionally, maternal immuniza-
tion with a formalin-inactivated whole-virus vac-
cine prolonged the survival of pups after EV71 
lethal challenge.
In a study by Wu et al, the inactivated virus vac-
cine (10 μg protein/mouse), and subunit vaccines—
VP1 DNA vaccine (100 μg/mouse) or recombinant VP1 
protein (10 μg/mouse)—were injected into female 
dams to elicit maternal antibodies and to provide 
protection against lethal infection by EV71 in suck-
ling mice.39 With a challenge dose of 2300 50% le-
thal dose (LD50) virus/mouse, suckling mice born to 
dams immunized with inactivated virus showed 80% 
survival. The subunit vaccines provided protection 
only at the lower challenge dose of 230 LD50 per 
mouse, with 40% survival for the DNA vaccine and 
80% survival for the VP1 protein. In addition, the 
inactivated virus elicited a much greater immune 
response than the subunit vaccines, including total 
IgG, all four IgG subtypes, and T-helper cell respon-
ses. This data suggests that an inactivated virus is the 
preferred vaccine preparation.
Animal studies with newborn mice are still in 
progress, and studies with monkeys or chimpanzees 
may be performed in the near future. It is hoped 
that an EV71 vaccine can be developed to control 
future epidemics in Asian-Pacific areas.
In conclusion, EV71 is one of the most impor-
tant enteroviruses worldwide, and continued EV71 
disease and laboratory surveillance in Taiwan is 
essential. The development of anti-EV71 drugs and 
vaccines may provide the most promise for the 
control of epidemics. Much research is currently 
being carried out in Taiwan aimed at developing ef-
fective control measures, including the development 
of antiviral drugs and EV71 vaccines.
References
1. Schmidt NJ, Lennette EH, Ho HH. An apparently new entero-
virus isolated from patients with disease of the central 
nervous system. J Infect Dis 1974;129:304−9.
2. Shindarov LM, Chumakov MP, Voroshilova MK, et al. 
Epidemiological, clinical and pathomorphological charac-
teristics of epidemic poliomyelitis-like disease caused by 
entero virus 71. J Hyg Epidemiol Microbiol Immunol 1979;
23:284−95.
3. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological 
diagnosis of enterovirus type 71 infections: experiences 
gained during an epidemic of acute CNS diseases in Hungary 
in 1978. Arch Virol 1982;71:217−27.
4. Chan LG, Parashar UD, Lye MS, et al. Deaths of children dur-
ing an outbreak of hand, foot, and mouth disease in Sarawak, 
Malaysia: clinical and pathological characteristics of the dis-
ease. Clin Infect Dis 2000;31:678−83.
5. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 
infection in Taiwan. N Eng J Med 1999;341:929−35.
6. Chang LY, CC King, KH Hsu, et al. Risk factors of enterovirus 
71 infection and associated hand-foot-mouth-disease/
herpangina in children. Pediatrics 2002;109:e88.
7. Lu CY, Lee CY, Kao CL, et al. Incidence and case–fatality rates 
resulting from the 1998 enterovirus 71 outbreak in Taiwan. 
J Med Virol 2002;67:217−23.
8. Chu PY, Lin KH, Hwang KP, et al. Molecular epidemiology of 
enterovirus 71 in Taiwan. Arch Virol 2001;146:589−600.
9. Chang LY, Lee CY, Kao CL, et al. Hand, foot and mouth dis-
ease complicated with central nervous system involvement 
in Taiwan in 1980−1981. J Formos Med Assoc 2007;106:173−6.
10. Wu TN, Tsai SF, Li SF, et al. Sentinel surveillance of enterovi-
rus 71, Taiwan, 1998. Emerg Infect Dis 1999;5:458−60.
11. Chen SC, Chang HL, Yan TR, Cheng YT, Chen KT. An eight-year 
study of epidemiologic features of enterovirus 71 infection 
in Taiwan. Am J Trop Med Hyg 2007;77:188−91.
12. Taiwan CDC. Locations of 13 Contract Laboratories. Available 
at: http://www.cdc.gov.tw/index_info.asp?p_data_id_2=331&
act=init. [Date accessed: August 13, 2008]
13. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic 
features of hand-foot-mouth disease and herpangina caused 
by enterovirus 71 in Taiwan, 1998−2005. Pediatrics 2007;
120:e244−52.
14. Chang LY, Lin TY, Huang YC, et al. Comparison of enterovi-
rus 71 and Coxsackievirus A16 clinical illness during the 
Taiwan enterovirus epidemic, 1998. Ped Infect Dis J 1999;
18:1092−6.
15. Gelfand HM, LeBlanc DR, Fox JP, Conwell DP. Studies on the 
development of natural immunity to poliomyelitis in 
Louisiana. II. Description and analysis of episodes of infection 
112 L.Y. Chang
observed in study group households. Am J Hyg 1957;65:
367−85.
16. Kogon A, Spigland I, Frothingham TE, et al. The Virus Watch 
program: a continuing surveillance of viral infections in met-
ropolitan New York families. VII. Observations on viral excre-
tion, seroimmunity, intrafamilial spread and illness association 
in Coxsackie and echovirus infections. Am J Epidemiol 
1969;89:51−61.
17. Morens DM, Pallansch MA, Moore M. Polioviruses and 
other enteroviruses. In: Belshe RB, ed. Textbook of Human 
Virology, 2nd edition. St. Louis, MO: Mosby Yearbook, 1991:
427−97.
18. Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical 
features of enterovirus 71 infections in household contacts 
in Taiwan. JAMA 2004;291:222−7.
19. Chung PW, Huang YC, Chang LY, Lin TY, Ning HC. Duration of 
enterovirus shedding in stool. J Microbiol Immunol Infect 
2001;34:167−70.
20. Chang LY, Lin TY, Hsu KH, et al. Clinical features and 
risk factors of pulmonary oedema after enterovirus 
71-related hand, foot, and mouth disease. Lancet 1999;
354:1682−6.
21. Chang LY, Hsia SH, Wu CT, et al. Outcome of EV71 infec-
tions with or without stage-based management, 1998−2002. 
Pediatr Infect Dis J 2004;23:327−31.
22. Lin TY, Chang LY, Hsai SH, et al. The 1998 enterovirus 71 out-
break in Taiwan: pathogenesis and management. Clin Infect 
Dis 2002;34:S52−7.
23. Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. 
Neurologic complications in children with enterovirus 71 
infection. N Engl J Med 1999;341:936−42.
24. Hsueh C, Jung SM, Shih SR, et al. Acute and fatal encepha-
lomyelitis during an outbreak of enterovirus type 71 infec-
tion in Taiwan: report of an autopsy case with pathologic, 
immunofluorescence and molecular studies. Mod Pathol 2000;
13:1200−5.
25. Lum LCS, Wong KT, Lam SK, et al. Fatal enterovirus 71 
encephalomyelitis. J Pediatr 1998;133:795−8.
26. Lin TY, Chang LY, Huang YC, et al. Different proinflammatory 
reactions in fatal and nonfatal enterovirus 71 infections: 
implications for early recognition and therapy. Acta Paediatr 
2002;91:632−5.
27. Wang SM, Lei HY, Huang KJ, et al. Pathogenesis of enterovi-
rus 71 brainstem encephalitis in pediatric patients: roles of 
cytokines and cellular immune activation in patients with 
pulmonary edema. J Infect Dis 2003;188:564−70.
28. Lin TY, Hsia SH, Huang YC, Wu CT, Chang LY. Proinflammatory 
cytokine reactions in enterovirus 71 infections of the central 
nervous system. Clin Infect Dis 2003;36:269−74.
29. Yang KD, Yang MY, Li CC, et al. Altered cellular but not 
humoral reactions in children with complicated ente rovirus 
71 infections in Taiwan. J Infect Dis 2001;183:850−6.
30. Chang LY, Hsiung CA, Lu CY, et al. Status of cellular rather 
than humoral immunity is correlated with clinical outcome 
of enterovirus 71. Pediatr Res 2006;60:466−71.
31. Chang LY, Huang LM, Gau SF, et al. Neurodevelopment and 
cognition in children after enterovirus 71 infection. N Engl 
J Med 2007;356:1226−34.
32. Shih SR, Chen SJ, Hakimelahi GH, Liu HJ, Tseng CT, Shia KS. 
Selective human enterovirus and rhinovirus inhibitors: an 
overview of capsid-binding and protease-inhibiting molecules. 
Med Res Rev 2004;24:449−74.
33. Groarke JM, Pevear DC. Attenuated virulence of pleconaril-
resistant Coxsackievirus B3 variants. J Infect Dis 1999;179:
1538−41.
34. Shia KS, Li WT, Chang CM, et al. Design, synthesis, and 
structure-activity relationship of pyridyl imidazolidinones: 
a novel class of potent and selective human enterovirus 71 
inhibitors. J Med Chem 2002;45:1644−55.
35. Shih SR, Tsai MC, Tseng SN, et al. Mutation in enterovirus 
71 capsid protein VP1 confers resistance to the inhibitory 
effects of pyridyl imidazolidinone. Antimicrob Agents 
Chemother 2004;48:3523−9.
36. Chern JH, Shia KS, Hsu TA, et al. Design, synthesis, and 
structure-activity relationships of pyrazolo[3,4-d]pyrimi-
dines: a novel class of potent enterovirus inhibitors. Bioorg 
Med Chem Lett 2004;14:2519−25.
37. Taiwan CDC. Notifiable Infectious Diseases Statistics Systems: 
Severe Enteroviral Cases. Available at: http://nidss.cdc.
gov.tw/singledisease.aspx?pt = s&dc = 1&dt = 3&disease = 07
49. [Date accessed: August 13, 2008]
38. Yu CK, Chen CC, Chen CL, et al. Neutralizing antibody pro-
vided protection against enterovirus type 71 lethal chal-
lenge in neonatal mice. J Biomed Sci 2000;7:523−8.
39. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection 
against lethal enterovirus 71 infection in newborn mice by 
passive immunization with subunit VP1 vaccines and inacti-
vated virus. Vaccine 2001;20:895−904.
